Calmy Alexandra, Ford Nathan, Hirschel Bernard, Reynolds Steven J, Lynen Lut, Goemaere Eric, Garcia de la Vega Felipe, Perrin Luc, Rodriguez William
Medecins sans Frontieres, Access to Medicines Campaign, Geneva, 1211, Switzerland.
Clin Infect Dis. 2007 Jan 1;44(1):128-34. doi: 10.1086/510073. Epub 2006 Nov 28.
Although it is a standard practice in high-income countries, determination of the human immunodeficiency virus (HIV) load is not recommended in developing countries because of the costs and technical constraints. As more and more countries establish capacity to provide second-line therapy, and as costs and technological constraints associated with viral load testing decrease, the question of whether determination of the viral load is necessary deserves attention. Viral load testing could increase in importance as a guide for clinical decisions on when to switch to second-line treatment and on how to optimize the duration of the first-line treatment regimen. In addition, the viral load is a particularly useful tool for monitoring adherence to treatment, performing sentinel surveillance, and diagnosing HIV infection in children aged <18 months. Rather than considering viral load data to be an unaffordable luxury, efforts should be made to ensure that viral load testing becomes affordable, simple, and easy to use in resource-limited settings.
尽管在高收入国家这是一种标准做法,但由于成本和技术限制,在发展中国家不建议进行人类免疫缺陷病毒(HIV)载量测定。随着越来越多的国家建立起提供二线治疗的能力,并且与病毒载量检测相关的成本和技术限制降低,病毒载量测定是否必要的问题值得关注。作为何时切换到二线治疗以及如何优化一线治疗方案疗程的临床决策指南,病毒载量检测的重要性可能会增加。此外,病毒载量是监测治疗依从性、进行哨点监测以及诊断18个月以下儿童HIV感染的特别有用的工具。不应将病毒载量数据视为负担不起的奢侈品,而应努力确保在资源有限的环境中病毒载量检测变得负担得起、操作简单且易于使用。